Browse by Research Team

Article

Expression of mGluR5 in pediatric Hodgkin and Non-Hodgkin lymphoma-a comparative analysis of immunohistochemical and clinical findings regarding the association between tumor and paraneoplastic neurological disease.
Viezens, I., Knierim, E., Deubzer, H.E., Hauptmann, K., Fassbender, J., Morales-Gonzalez, S., Kaindl, A.M., Schuelke, M. and Nikolaus, M.
Cancers 16 (13): 2452. 4 July 2024

L-glyceraldehyde inhibits neuroblastoma cell growth via a multi-modal mechanism on metabolism and Signaling.
Forbes, M., Kempa, R., Mastrobuoni, G., Rayman, L., Pietzke, M., Bayram, S., Arlt, B., Spruessel, A., Deubzer, H.E. and Kempa, S.
Cancers 16 (9): 1664. May 2024

Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing.
Rensing-Ehl, A., Lorenz, M.R., Führer, M., Willenbacher, W., Willenbacher, E., Sopper, S., Abinun, M., Maccari, M.E., König, C., Haegele, P., Fuchs, S., Castro, C., Kury, P., Pelle, O., Klemann, C., Heeg, M., Thalhammer, J., Wegehaupt, O., Fischer, M., Goldacker, S., Schulte, B., Biskup, S., Chatelain, P., Schuster, V., Warnatz, K., Grimbacher, B., Meinhardt, A., Holzinger, D., Oommen, P.T., Hinze, T., Hebart, H., Seeger, K., Lehmberg, K., Leahy, T.R., Claviez, A., Vieth, S., Schilling, F.H., Fuchs, I., Groß, M., Rieux-Laucat, F., Magerus, A., Speckmann, C., Schwarz, K. and Ehl, S.
Journal of Allergy and Clinical Immunology 153 (1): 297-308. January 2024

Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN.
Fuchs, S., Danßmann, C., Klironomos, F., Winkler, A., Fallmann, J., Kruetzfeldt, L.M., Szymansky, A., Naderi, J., Bernhart, S.H., Grunewald, L., Helmsauer, K., Rodriguez-Fos, E., Kirchner, M., Mertins, P., Astrahantseff, K., Suenkel, C., Toedling, J., Meggetto, F., Remke, M., Stadler, P.F., Hundsdoerfer, P., Deubzer, H.E., Künkele, A., Lang, P., Fuchs, J., Henssen, A.G., Eggert, A., Rajewsky, N., Hertwig, F. and Schulte, J.H.
Nature Communications 14 (1): 3936. 4 July 2023

Optimising urinary catecholamine metabolite diagnostics for neuroblastoma.
Matser, Y.A.H., Verly, I.R.N., van der Ham, M., de Sain‐van der Velden, M.G.M., Verhoeven‐Duif, N.M., Ash, S., Cangemi, G., Barco, S., Popovic, M.B., van Kuilenburg, A.B.P. and Tytgat, G.A.M.
Pediatric Blood and Cancer 70 (6): e30289. June 2023

Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells.
Chamorro González, R., Conrad, T., Stöber, M.C., Xu, R., Giurgiu, M., Rodriguez-Fos, E., Kasack, K., Brückner, L., van Leen, E., Helmsauer, K., Dorado Garcia, H., Stefanova, M.E., Hung, K.L., Bei, Y., Schmelz, K., Lodrini, M., Mundlos, S., Chang, H.Y., Deubzer, H.E., Sauer, S., Eggert, A., Schulte, J.H., Schwarz, R.F., Haase, K., Koche, R.P. and Henssen, A.G.
Nature Genetics 55 (5): 880-890. May 2023

Treatment of infants and children with SARS-CoV-2 monoclonal antibodies: a European case series.
Rau, C., Auer-Hackenberg, L., Deubzer, H.E., Schwabel, E., Jaros, M., Diederichs, A., Lehrnbecher, T., Holm, M., von Linstow, M.L., Martin, L., Dinges, S.S., Rothensteiner, M., Siepermann, M., Strenger, V., von Both, U., Teig, N., Brinkmann, F., Leeb, F., Zeitlinger, M., Kobbe, R. and Götzinger, F.
Pediatric Infectious Disease Journal 42 (2): 125-129. February 2023

Efficacy and feasibility of proton beam therapy in relapsed high-risk neuroblastoma-experiences from the prospective KiProReg registry.
Jazmati, D., Hero, B., Thole-Kliesch, T.M., Merta, J., Deubzer, H.E., Bäumer, C., Heinzelmann, F., Schleithoff, S.S., Koerber, F., Eggert, A., Schwarz, R., Simon, T. and Timmermann, B.
Current Oncology 29 (11): 8222-8234. November 2022

Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.
Eichinger, A., Poetschger, U., Glogova, E., Bader, P., Basu, O., Beier, R., Burkhardt, B., Classen, C.F., Claviez, A., Corbacioglu, S., Deubzer, H.E., Greil, J., Gruhn, B., Güngör, T., Kafa, K., Kühl, J.S., Lang, P., Lange, B.S., Meisel, R., Müller, I., Sauer, M.G., Schlegel, P.G., Schulz, A., Stachel, D., Strahm, B., Wawer, A., Peters, C. and Albert, M.H.
Leukemia 36 (11): 2567-2576. November 2022

Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRAS-mutant neurocutaneous melanosis.
Schweizer, L., Hartmann, W., Koch, A., Nunninger, M., Thomale, U.W., Pennacchietti, V., Tietze, A., Horn, D., Pajtler, K.W., Hirsch, S., Wieland, I., Deubzer, H., Rossi, R., Hernáiz Driever, P., von Hoff, K. and von Zezschwitz, B.
Neuropathology and Applied Neurobiology 48 (6): e12830. October 2022

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak, M., Tucker, E., Dorel, M., Winkler, A., McGearey, A., Rodriguez-Fos, E., da Costa, B.M., Barker, K., Fyle, E., Calton, E., Eising, S., Ober, K., Hughes, D., Koutroumanidou, E., Carter, P., Stankunaite, R., Proszek, P., Jain, N., Rosswog, C., Dorado-Garcia, H., Molenaar, J.J., Hubank, M., Barone, G., Anderson, J., Lang, P., Deubzer, H.E., Künkele, A., Fischer, M., Eggert, A., Kloft, C., Henssen, A.G., Boettcher, M., Hertwig, F., Blüthgen, N., Chesler, L. and Schulte, J.H.
Molecular Cancer 21 (1): 126. 10 June 2022

Genomic evolution and personalized therapy of an infantile fibrosarcoma harboring an NTRK oncogenic fusion.
Thorwarth, A., Haase, K., Röefzaad, C., Pajtler, K.W., Schramm, K., Hauptmann, K., Behnke, A., Vokuhl, C., Elgeti, T., Gratopp, A., Schulte, J.H., Scheer, M., Hernáiz Driever, P., Nysom, K., Eggert, A., Henssen, A.G. and Deubzer, H.E.
JCO Precision Oncology 6 : e2100283. 25 May 2022

Targeted analysis of cell-free circulating tumor DNA is suitable for early relapse and actionable target detection in patients with neuroblastoma.
Lodrini, M., Graef, J., Thole-Kliesch, T.M., Astrahantseff, K., Sprüssel, A., Grimaldi, M., Peitz, C., Linke, R.B., Hollander, J.F., Lankes, E., Künkele, A., Oevermann, L., Schwabe, G., Fuchs, J., Szymansky, A., Schulte, J.H., Hundsdoerfer, P., Eckert, C., Amthauer, H., Eggert, A. and Deubzer, H.E.
Clinical Cancer Research 28 (9): 1809-1820. 1 May 2022

Circulating cell-free DNA assessment in biofluids from children with neuroblastoma demonstrates feasibility and potential for minimally invasive molecular diagnostics.
Lodrini, M., Wünschel, J., Thole-Kliesch, T.M., Grimaldi, M., Sprüssel, A., Linke, R.B., Hollander, J.F., Tiburtius, D., Künkele, A., Schulte, J.H., Lankes, E., Elgeti, T., Hundsdörfer, P., Astrahantseff, K., Simon, T., Eggert, A. and Deubzer, H.E.
Cancers 14 (9): 2080. 21 April 2022

Hemostatic management in an infant with neuroblastoma and severe hemophilia B with extended half-life recombinant factor IX fusion protein.
Cuntz, F., Deubzer, H.E., Schulte, J.H., Nimtz-Talaska, A., Eggert, A. and Holzhauer, S.
Journal of Pediatric Hematology Oncology 44 (1): e246-e249. 1 January 2022

Bioprinted cancer model of neuroblastoma in a renal microenvironment as an efficiently applicable drug testing platform.
Wu, D., Berg, J., Arlt, B., Röhrs, V., Al-Zeer, M.A., Deubzer, H.E. and Kurreck, J.
International Journal of Molecular Sciences 23 (1): 122. 23 December 2021

Neuroblastoma risk assessment and treatment stratification with hybrid capture-based panel sequencing.
Szymansky, A., Kruetzfeldt, L.M., Heukamp, L.C., Hertwig, F., Theissen, J., Deubzer, H.E., Willing, E.M., Menon, R., Fuchs, S., Thole, T., Schulte, S., Schmelz, K., Künkele, A., Lang, P., Fuchs, J., Eggert, A., Eckert, C., Fischer, M., Henssen, A.G., Rodriguez-Fos, E. and Schulte, J.H.
Journal of Personalized Medicine 11 (8): 691. August 2021

Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect.
Arlt, B., Mastrobuoni, G., Wuenschel, J., Astrahantseff, K., Eggert, A., Kempa, S. and Deubzer, H.E.
Journal of Enzyme Inhibition and Medicinal Chemistry 36 (1): 1282-1289. 30 June 2021

A reproducible bioprinted 3D tumor model serves as a preselection tool for CAR T cell therapy optimization.
Grunewald, L., Lam, T., Andersch, L., Klaus, A., Schwiebert, S., Winkler, A., Gauert, A., Heeren-Hagemann, A.I., Astrahantseff, K., Klironomos, F., Thomas, A., Deubzer, H.E., Henssen, A.G., Eggert, A., Schulte, J.H., Anders, K., Kloke, L. and Künkele, A.
Frontiers in Immunology 12 : 689697. 29 June 2021

Germline mutations including the rare pathogenic variant c.3206delC in the ATM gene cause ataxia teleangiectasia-associated primary central nervous system lymphoma.
Dörr, J.R., Thorwarth, A., Mizia-Malarz, A., Radke, J., Tietze, A., Hernáiz-Driever, P., Horn, D., Gratopp, A., Eggert, A. and Deubzer, H.E.
Children 8 (6): 469. June 2021

„Liquid biopsies“ als neue Diagnostikplattform in der pädiatrischen Onkologie [Liquid biopsies as a new diagnostic platform in pediatric oncology].
Deubzer, H.E., Eggert, A. and Pajtler, K. W.
Onkologe 27 (5): 458-463. May 2021

Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Arlt, B., Zasada, C., Baum, K., Wuenschel, J., Mastrobuoni, G., Lodrini, M., Astrahantseff, K., Winkler, A., Schulte, J.H., Finkler, S., Forbes, M., Hundsdoerfer, P., Guergen, D., Hoffmann, J., Wolf, J., Eggert, A., Kempa, S. and Deubzer, H.E.
International Journal of Cancer 148 (5): 1219-1232. 1 March 2021

Clinical presentation and management of a dinutuximab beta extravasation in a patient with neuroblastoma.
Launspach, M., Seif, M., Thole, TM., Jesse, P., Schulz, J., Schulte, J.H., Bischoff, S., Eggert, A. and Deubzer, H.E.
Children 8 (2): 91. 29 January 2021

Multiplexed quantification of four neuroblastoma DNA targets in a single droplet digital PCR reaction.
Peitz, C., Sprüssel, A., Linke, R.B., Astrahantseff, K., Grimaldi, M., Schmelz, K., Toedling, J., Schulte, J.H., Fischer, M., Messerschmidt, C., Beule, D., Keilholz, U., Eggert, A., Deubzer, H.E. and Lodrini, M.
Journal of Molecular Diagnostics 22 (11): 1309-1323. November 2020

Sinusoidal obstruction syndrome following myeloablative therapy and tranexamic acid treatment for hemorrhage in two patients with neuroblastoma.
Zirngibl, F., Flemmig, C., Lang, P., Künkele, A., Eggert, A., Schulte, J.H. and Deubzer, H.E.
Children 7 (11): 198. November 2020

Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Toews, K., Grunewald, L., Schwiebert, S., Klaus, A., Winkler, A., Ali, S., Zirngibl, F., Astrahantseff, K., Wagner, D.L., Henssen, A.G., Deubzer, H.E., Schulte, J.H., Ochsenreither, S., Eggert, A. and Künkele, A.
Molecular Carcinogenesis 59 (7): 724-273. July 2020

Tumor-derived extracellular vesicles impair CD171-specific CD4(+) CAR T cell efficacy.
Ali, S., Toews, K., Schwiebert, S., Klaus, A., Winkler, A., Grunewald, L., Oevermann, L., Deubzer, H.E., Tüns, A., Jensen, M.C., Henssen, A.G., Eggert, A., Schulte, J.H., Schwich, E., Rebmann, V., Schramm, A. and Künkele, A.
Frontiers in Immunology 11 : 531. 31 March 2020

Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model.
Thole, T.M., Toedling, J., Sprüssel, A., Pfeil, S., Savelyeva, L., Capper, D., Messerschmidt, C., Beule, D., Groeneveld-Krentz, S., Eckert, C., Gambara, G., Henssen, A.G., Finkler, S., Schulte, J.H., Sieber, A., Bluethgen, N., Regenbrecht, C.R.A., Künkele, A., Lodrini, M., Eggert, A. and Deubzer, H.E.
International Journal of Cancer 146 (4): 1031-1041. 15 February 2020

Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma.
Koche, R.P., Rodriguez-Fos, E., Helmsauer, K., Burkert, M., MacArthur, I.C., Maag, J., Chamorro, R., Munoz-Perez, N., Puiggròs, M., Dorado Garcia, H., Bei, Y., Röefzaad, C., Bardinet, V., Szymansky, A., Winkler, A., Thole, T., Timme, N., Kasack, K., Fuchs, S., Klironomos, F., Thiessen, N., Blanc, E., Schmelz, K., Künkele, A., Hundsdörfer, P., Rosswog, C., Theissen, J., Beule, D., Deubzer, H., Sauer, S., Toedling, J., Fischer, M., Hertwig, F., Schwarz, R.F., Eggert, A., Torrents, D., Schulte, J.H. and Henssen, A.G.
Nature Genetics 52 (1): 29-34. January 2020

Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han, Y., Lindner, S., Bei, Y., Garcia, H.D., Timme, N., Althoff, K., Odersky, A., Schramm, A., Lissat, A., Künkele, A., Deubzer, H.E., Eggert, A., Schulte, J.H. and Henssen, A.G.
Cancer Letters 445 : 24-33. 31 March 2019

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.
Arnhold, V., Schmelz, K., Proba, J., Winkler, A., Wünschel, J., Toedling, J., Deubzer, H.E., Künkele, A., Eggert, A., Schulte, J.H. and Hundsdoerfer, P.
Oncotarget 9 (2): 2304-2319. 2018

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.
Lodrini, M., Sprüssel, A., Astrahantseff, K., Tiburtius, D., Konschak, R., Lode, H.N., Fischer, M., Keilholz, U., Eggert, A. and Deubzer, H.E.
Oncotarget 8 (49): 85234-85251. 17 October 2017

2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors.
Simon, T., Hero, B., Schulte, J.H., Deubzer, H., Hundsdoerfer, P., von Schweinitz, D., Fuchs, J., Schmidt, M., Prasad, V., Krug, B., Timmermann, B., Leuschner, I., Fischer, M., Langer, T., Astrahantseff, K., Berthold, F., Lode, H. and Eggert, A.
Klinische Padiatrie 229 (3): 147-167. May 2017

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
Gottlieb, A., Althoff, K., Grunewald, L., Thor, T., Odersky, A., Schulte, M., Deubzer, H.E., Heukamp, L., Eggert, A., Schramm, A., Schulte, J.H. and Künkele, A.
Oncotarget 8 (17): 27882-27891. 25 April 2017

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.
Thole, T.M., Lodrini, M., Fabian, J., Wuenschel, J., Pfeil, S., Hielscher, T., Kopp-Schneider, A., Heinicke, U., Fulda, S., Witt, O., Eggert, A., Fischer, M. and Deubzer, H.E.
Cell Death & Disease 8 (3): e2635. 2 March 2017

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler, K.W., Sadowski, N., Ackermann, S., Althoff, K., Schönbeck, K., Batzke, K., Schäfers, S., Odersky, A., Heukamp, L., Astrahantseff, K., Künkele, A., Deubzer, H.E., Schramm, A., Sprüssel, A., Thor, T., Lindner, S., Eggert, A., Fischer, M. and Schulte, J.H.
Oncotarget 8 (4): 6730-6741. 24 January 2017

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Fabian, J., Opitz, D., Althoff, K., Lodrini, M., Hero, B., Volland, R., Beckers, A., de Preter, K., Decock, A., Patil, N., Abba, M., Kopp-Schneider, A., Astrahantseff, K., Wünschel, J., Pfeil, S., Ercu, M., Künkele, A., Hu, J., Thole, T., Schweizer, L., Mechtersheimer, G., Carter, D., Cheung, B.B., Popanda, O., von Deimling, A., Koster, J., Versteeg, R., Schwab, M., Marshall, G.M., Speleman, F., Erb, U., Zoeller, M., Allgayer, H., Simon, T., Fischer, M., Kulozik, A.E., Eggert, A., Witt, O., Schulte, J.H. and Deubzer, H.E.
Oncotarget 7 (41): 66344-66359. 11 October 2016

Minichromosome maintenance complex is a critical node in the miR-183 signaling network of MYCN-amplified neuroblastoma cells.
Lodrini, M., Poschmann, G., Schmidt, V., Wünschel, J., Dreidax, D., Witt, O., Höfer, T., Meyer, H.E., Stühler, K., Eggert, A. and Deubzer, H.E.
Journal of Proteome Research 15 (7): 2178-2186. 1 July 2016

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Ecker, J., Oehme, I., Mazitschek, R., Korshunov, A., Kool, M., Hielscher, T., Kiss, J., Selt, F., Konrad, C., Lodrini, M., Deubzer, H.E., von Deimling, A., Kulozik, A.E., Pfister, S.M., Witt, O. and Milde, T.
Acta Neuropathologica Communications 3 : 22. 3 April 2015

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
Rettig, I., Koeneke, E., Trippel, F., Mueller, W.C., Burhenne, J., Kopp-Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., Deubzer, H.E., Milde, T., Witt, O. and Oehme, I.
Cell Death & Disease 6 : e1657. 19 February 2015

GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian, J., Lodrini, M., Oehme, I., Schier, M.C., Thole, T.M., Hielscher, T., Kopp-Schneider, A., Opitz, L., Capper, D., von Deimling, A., Wiegand, I., Milde, T., Mahlknecht, U., Westermann, F., Popanda, O., Roels, F., Hero, B., Berthold, F., Fischer, M., Kulozik, A.E., Witt, O. and Deubzer, H.E.
Cancer Research 74 (9): 2604-2616. 1 May 2014

Histone deacetylase 10 promotes autophagy-mediated cell survival.
Oehme, I., Linke, J.P., Böck, B.C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., Kaden, S., Gröne, H.J., Schulte, J.H., Lindner, S., Hamacher-Brady, A., Brady, N.R., Deubzer, H.E. and Witt, O.
Proceedings of the National Academy of Sciences of the United States of America 110 (28): E2592-E2601. 9 July 2013

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H.E., Rycak, L., Jamin, Y., Thway, K., Robinson, S.P., Roels, F., Witt, O., Fischer, M., Chesler, L. and Eilers, M.
Cancer Cell 24 (1): 75-89. 8 July 2013

MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
Lodrini, M., Oehme, I., Schroeder, C., Milde, T., Schier, M.C., Kopp-Schneider, A., Schulte, J.H., Fischer, M., De Preter, K., Pattyn, F., Castoldi, M., Muckenthaler, M.U., Kulozik, A.E., Westermann, F., Witt, O. and Deubzer, H.E.
Nucleic Acids Research 41 (12): 6018-6033. 1 July 2013

HDAC11 is a novel drug target in carcinomas.
Deubzer, H.E., Schier, M.C., Oehme, I., Lodrini, M., Haendler, B., Sommer, A. and Witt, O.
International Journal of Cancer 132 (9): 2200-2208. 1 May 2013

Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma.
Kocak, H., Ackermann, S., Hero, B., Kahlert, Y., Oberthuer, A., Juraeva, D., Roels, F., Theissen, J., Westermann, F., Deubzer, H., Ehemann, V., Brors, B., Odenthal, M., Berthold, F. and Fischer, M.
Cell Death & Disease 4 : e586. 11 April 2013

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Milde, T., Lodrini, M., Savelyeva, L., Korshunov, A., Kool, M., Brueckner, L.M., Antunes, A.S.L.M., Oehme, I., Pekrun, A., Pfister, S.M., Kulozik, A.E., Witt, O. and Deubzer, H.E.
Journal of Neuro-Oncology 110 (3): 335-348. December 2012

Nestin expression identifies ependymoma patients with poor outcome.
Milde, T., Hielscher, T., Witt, H., Kool, M., Mack, S.C., Deubzer, H.E., Oehme, I., Lodrini, M., Benner, A., Taylor, M.D., von Deimling, A., Kulozik, A.E., Pfister, S.M., Witt, O. and Korshunov, A.
Brain Pathology 22 (6): 848-860. November 2012

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia.
Witt, O., Milde, T., Deubzer, H.E., Oehme, I., Witt, R., Kulozik, A., Eisenmenger, A., Abel, U. and Karapanagiotou-Schenkel, I.
Klinische Padiatrie 224 (6): 398-403. October 2012

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele, A., De Preter, K., Heukamp, L., Thor, T., Pajtler, K.W., Hartmann, W., Mittelbronn, M., Grotzer, M.A., Deubzer, H.E., Speleman, F., Schramm, A., Eggert, A. and Schulte, J.H.
Neuro-Oncology 14 (7): 859-869. 1 July 2012

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
Milde, T., Kleber, S., Korshunov, A., Witt, H., Hielscher, T., Koch, P., Kopp, H.G., Jugold, M., Deubzer, H.E., Oehme, I., Lodrini, M., Gröne, H.J., Benner, A., Brüstle, O., Gilbertson, R.J., von Deimling, A., Kulozik, A.E., Pfister, S.M., Martin-Villalba, A. and Witt, O.
Acta Neuropathologica 122 (5): 637-650. November 2011

CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells.
Henrich, K.O., Bauer, T., Schulte, J., Ehemann, V., Deubzer, H., Gogolin, S., Muth, D., Fischer, M., Benner, A., König, R., Schwab, M. and Westermann, F.
Cancer Research 71 (8): 3142-3151. 15 April 2011

Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Blattmann, C., Oertel, S., Ehemann, V., Thiemann, M., Huber, P.E., Bischof, M., Witt, O., Deubzer, H.E., Kulozik, A.E., Debus, J. and Weber, K.J.
International Journal of Radiation Oncology, Biology, Physics 78 (1): 237-245. 1 September 2010

Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.
Lacroix, J., Leuchs, B., Li, J., Hristov, G., Deubzer, H.E., Kulozik, A.E., Rommelaere, J., Schlehofer, J.R. and Witt, O.
International Journal of Cancer 127 (5): 1230-1239. 1 September 2010

HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
Milde, T., Oehme, I., Korshunov, A., Kopp-Schneider, A., Remke, M., Northcott, P., Deubzer, H.E., Lodrini, M., Taylor, M.D., von Deimling, A., Pfister, S. and Witt, O.
Clinical Cancer Research 16 (12): 3240-3252. 15 June 2010

Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines.
Michaelis, M., Kleinschmidt, M.C., Barth, S., Rothweiler, F., Geiler, J., Breitling, R., Mayer, B., Deubzer, H., Witt, O., Kreuter, J., Doerr, H.W., Cinatl, J. and Cinatl, J.
Biochemical Pharmacology 79 (2): 130-136. 15 January 2010

Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma.
Milde, T., Pfister, S., Korshunov, K., Deubzer, H.E., Oehme, I., Ernst, A., Starzinski-Powitz, A., Seitz, A., Lichter, P., von Deimling, A. and Witt, O.
Genes Chromosomes & Cancer 48 (3): 229-238. March 2009

Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme, I., Deubzer, H.E., Wegener, D., Pickert, D., Linke, J.P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S.M., von Deimling, A., Fischer, M. and Witt, O.
Clinical Cancer Research 15 (1): 91-99. January 2009

Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells.
Schulte, J.H., Kirfel, J., Lim, S., Schramm, A., Friedrichs, N., Deubzer, H.E., Witt, O., Eggert, A. and Buettner, R.
Cancer Letters 271 (1): 56-63. 18 November 2008

Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis, M., Bliss, J., Arnold, S.C., Hinsch, N., Rothweiler, F., Deubzer, H.E., Witt, O., Langer, K., Doerr, H.W., Wels, W.S. and Cinatl, J.
Clinical Cancer Research 14 (20): 6531-6537. 16 October 2008

HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.
Wegener, D., Deubzer, H.E., Oehme, I., Milde, T., Hildmann, C., Schwienhorst, A. and Witt, O.
Anti-Cancer Drugs 19 (9): 849-857. October 2008

Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.
Wegener, D., Hildmann, C., Riester, D., Schober, A., Meyer-Almes, F.J., Deubzer, H.E., Oehme, I., Witt, O., Lang, S., Jaensch, M., Makarov, V., Lange, C., Busse, B. and Schwienhorst, A.
Biochemical Journal 413 (1): 143-150. 1 July 2008

Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro.
Deubzer, H.E., Ehemann, V., Kulozik, A.E., Westermann, F., Savelyeva, L., Kopp-Schneider, A., Riester, D., Schwab, M. and Witt, O.
Cancer Letters 264 (1): 21-28. 8 June 2008

Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells.
Deubzer, H.E., Ehemann, V., Westermann, F., Heinrich, R., Mechtersheimer, G., Kulozik, A.E., Schwab, M. and Witt, O.
International Journal of Cancer 122 (8): 1891-900. 15 April 2008

Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells.
Deubzer, H., Busche, B., Rönndahl, G., Eikel, D., Michaelis, M., Cinatl, J., Schulze, S., Nau, H. and Witt, O.
Leukemia Research 30 (9): 1167-1175. September 2006

Colostrum obtained from women vaccinated with pneumococcal vaccine during pregnancy inhibits epithelial adhesion of Streptococcus pneumoniae.
Deubzer, H.E., Obaro, S.K., Newman, V.O., Adegbola, R.A., Greenwood, B.M. and Henderson, D.C.
Journal of Infectious Diseases 190 (10): 1758-1761. 15 November 2004

Serotype-specific pneumococcal antibodies in breast milk of Gambian women immunized with a pneumococcal polysaccharide vaccine during pregnancy.
Obaro, S.K., Deubzer, H.E., Newman, V.O., Adegbola, R.A., Greenwood, B.M. and Henderson, D.C.
Pediatric Infectious Disease Journal 23 (11): 1023-1029. November 2004

Review

Management of malignant dysgerminoma of the ovary.
Arndt, T., Taube, E.T., Deubzer, H.E., Rothe, K., Calaminus, G., Sehouli, J. and Pietzner, K.
European Journal of Gynaecological Oncology 43 (2): 353-362. 15 April 2022

Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?
Deubzer, H.E., Schulte, J.H. and Eggert, A.
TumorDiagnostik & Therapie 43 (01): 29-44. February 2022

Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?
Deubzer, H.E., Schulte, J.H. and Eggert, A.
Pädiatrie up2date 16 (4): 325-342. December 2021

Accelerating drug development for neuroblastoma: summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno, L., Barone, G., DuBois, S.G., Molenaar, J., Fischer, M., Schulte, J., Eggert, A., Schleiermacher, G., Speleman, F., Chesler, L., Geoerger, B., Hogarty, M.D., Irwin, M.S., Bird, N., Blanchard, G.B., Buckland, S., Caron, H., Davis, S., De Wilde, B., Deubzer, H.E., Dolman, E., Eilers, M., George, R.E., George, S., Jaroslav, Š., Maris, J.M., Marshall, L., Merchant, M., Mortimer, P., Owens, C., Philpott, A., Poon, E., Shay, J.W., Tonelli, R., Valteau-Couanet, D., Vassal, G., Park, J.R. and Pearson, A.D.J.
European Journal of Cancer 136 : 52-68. September 2020

The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review.
Van Paemel, R., Vlug, R., De Preter, K., Van Roy, N., Speleman, F., Willems, L., Lammens, T., Laureys, G., Schleiermacher, G., Tytgat, G.A.M., Astrahantseff, K., Deubzer, H. and De Wilde, B.
European Journal of Pediatrics 179 : 191-202. February 2020

Childhood cancer predisposition syndromes - a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology.
Ripperger, T., Bielack, S.S., Borkhardt, A., Brecht, I.B., Burkhardt, B., Calaminus, G., Debatin, K.M., Deubzer, H., Dirksen, U., Eckert, C., Eggert, A., Erlacher, M., Fleischhack, G., Frühwald, M.C., Gnekow, A., Goehring, G., Graf, N., Hanenberg, H., Hauer, J., Hero, B., Hettmer, S., von Hoff, K., Horstmann, M., Hoyer, J., Illig, T., Kaatsch, P., Kappler, R., Kerl, K., Klingebiel, T., Kontny, U., Kordes, U., Körholz, D., Koscielniak, E., Kramm, C.M., Kuhlen, M., Kulozik, A.E., Lamottke, B., Leuschner, I., Lohmann, D.R., Meinhardt, A., Metzler, M., Meyer, L.H., Moser, O., Nathrath, M., Niemeyer, C.M., Nustede, R., Pajtler, K.W., Paret, C., Rasche, M., Reinhardt, D., Rieß, O., Russo, A., Rutkowski, S., Schlegelberger, B., Schneider, D., Schneppenheim, R., Schrappe, M., Schroeder, C., von Schweinitz, D., Simon, T., Sparber-Sauer, M., Spix, C., Stanulla, M., Steinemann, D., Strahm, B., Temming, P., Thomay, K., von Bueren, A.O., Vorwerk, P., Witt, O., Wlodarski, M., Wössmann, W., Zenker, M., Zimmermann, S., Pfister, S.M. and Kratz, C.P.
American Journal of Medical Genetics Part A 173 (4): 1017-1037. April 2017

Neuroblastoma imaging.
Ley, S., Ley-Zaporozhan, J., Günther, P., Deubzer, H.E., Witt, O. and Schenk, J.P.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 183 (3): 217-225. March 2011

Targeting of HDAC8 and investigational inhibitors in neuroblastoma.
Oehme, I., Deubzer, H.E., Lodrini, M., Milde, T. and Witt, O.
Expert Opinion on Investigational Drugs 18 (11): 1605-1617. November 2009

HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H.E., Milde, T. and Oehme, I.
Cancer Letters 277 (1): 8-21. 8 May 2009

Targeting histone deacetylases in neuroblastoma.
Witt, O., Deubzer, H.E., Lodrini, M., Milde, T. and Oehme, I.
Current Pharmaceutical Design 15 (4): 436-447. 2009

Letter

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B cell impairment and increases the risk for infections - a retrospective matched cohort study.
Launspach, M., Temel, D., Ohlendorf, E., Zirngibl, F., Materne, B., Oevermann, L., Deubzer, H.E., Henssen, A.G., Künkele, A., Hundsdörfer, P., von Bernuth, H., Pruß, A., Eggert, A., von Stackelberg, A., Lang, P. and Schulte, J.H.
Haematologica 108 (1): 267-272. January 2023

Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications.
Oevermann, L., Zimmermann, C., Voigt, S., Künkele, A., Lobitz, S., Eggert, A., Schulte, J.H., Kaufer, B.B. and Deubzer, H.E.
Bone Marrow Transplantation 55 (1): 260-264. January 2020

Editorial

A deep dive into the circulating ctDNA cosmos to vanquish neuroblastoma.
Deubzer, H.E., Astrahantseff, K. and Lodrini, M.
Cancer Discovery 12 (12): 2727-2729. 2 December 2022

Melanozytäre Naevi der Haut bei einem Neugeborenen [Dermal melanocytic nevi in a newborn].
Endres, S., Wilke, M., Höche, A., Gertz, A., Schubert, R., Deubzer, H., Eggert, A., Rossi, R. and Schlembach, D.
Gynäkologe 53 (8): 554-556. August 2020